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ABSTRACT Pemphigus vulgaris is an autoimmune disease that 
mostly affects the mucosa and oral cavity. Candida species can 
invade the mucosal lesions of these patients and cause diseases. 
The aim of this study was to identify the fungal agents isolated 
from mucosal lesions and evaluate antifungal activity profile 
against the isolates. A total of 25 patients with pemphigus vulgaris 
with active oral lesions and 25 healthy people serving as a control 
group were included in this study. Identification of the fungal iso-
lates was performed based on conventional methods and DNA se-
quence analysis of the internal transcribed spacer (ITS) rDNA gene 
region. The sequence results were deposited in the NCBI database 
using the Basic Local Alignment Search Tool. Antifungal activity of 
fluconazole, itraconazole, ketoconazole, posaconazole, econazole, 
and amphotericin B against the isolates were evaluated based on 
the CLSI M-44 A protocol.  Oral candidiasis was detected in 20% of 
the patients. Candida species isolated from oral lesions of patients 
with pemphigus were identified as Candida albicans 22/25, Candi-
da glabrata 2/25, and Candida dubliniensis 1/25. All of the isolates 
were sensitive to amphotericin and econazole, 96% to fluconazole 
and posaconazole, and 92% to ketoconazole and itraconazole. 
One patient showed a profile resistant to fluconazole, posacon-
azole, and ketoconazole, simultaneously. Ninety six percent of 
control group isolates were sensitive to six antifungals. Candida 
albicans was the most prevalent species isolated from oral lesions 
of patients with pemphigus vulgaris and the control group. Am-
photericin B and econazole were the most effective antifungals 
against the isolates.
KEY WORDS: pemphigus vulgaris, Candida, antifungal, ITS
INTRODUCTION
Pemphigus vulgaris (PV) is a chronic autoim-
mune mucocutaneous disease characterized by the 
formation of erosions, ulcers, and blisters on the 
mucosa and skin (1). Without corticosteroid therapy 
disease often leads to death (2). Despite other types 
of pemphigus such as pemphigus erythematosus, 
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foliaceus, and pemphigus vegetans, which rarely af-
fect the oral mucosa, oral lesions are common in 
pemphigus vulgaris and have a high frequency in pa-
tients (3). Oral lesions may associate with blisters on 
the lips, gum, and gingiva and are mostly painful (4). 
Corticosteroid therapy (such as prednisolone, 20 to 
120 mg/day) is prescribed in all cases to prevent the 
progression of the disease (5). It has been reported 
that corticosteroid therapy provides a suitable state 
for opportunist microorganisms to cause invasion 
and infections, which is the most common complica-
tion in patients with PV (1). Bacterial and viral agents 
were also reported in association with PV oral infec-
tions (6). Candida species are the most common cause 
of opportunistic infections and clinical manifestation 
due to fungi in patients with PV mostly being present 
as thrush or stomatitis, pharyngitis, and Pneumocystis 
carinii pneumonia (7).
There are many antifungal drugs used for pre-
vention and therapy in fungal infections. Failure in 
therapy commonly occurs in the antifungal resistant 
cases. 
The main aim of this study was the molecular 
identification of the fungal species associated with 
oral lesions in patients with pemphigus vulgaris by in-
ternal transcribed spacer (ITS) sequence analysis and 
antifungal activity evaluation of six antifungal drugs 
against the isolates with the disk diffusion method.
PATIENTS AND METHODS
Case and control group
A total of 25 cases with oral lesions from 40 pa-
tients with PV referred to pemphigus therapeutic 
clinic in Shiraz were enrolled in our study. The re-
search project was approved by the Ethics Commit-
tee of Departmental Review Board (Ethical code: 
IR.SUMS.REC.1396.S665) of the Shiraz University of 
Medical Sciences, Shiraz, Iran. The oral cavity of the 
patients was examined for any erosions, blisters, le-
sions, and localized plaques on the oral mucosa, and 
a sterile swap was taken from the suspected area. The 
swaps were speared on plates containing Sabouraud 
dextrose agar (Merck, Germany) supplemented with 
antibiotics (pen-strep, Norbrook, UK) and incubated 
at 30ºC. A total of 25 healthy people were chosen for 
the control group and matched with the case group 
in terms of age and sex. Swabs were taken from the 
oral cavity of the control group and cultured on the 
above media.  
Conventional identification methods 
Primary identification of isolates was based on mi-
cromorphological analysis based on yeast shape us-
ing a teased mount smear (round, ovoid, or rectangu-




Genomic DNA was extracted through the boiling 
method described by Makimura et al. (8) with small 
modifications. Briefly, a small amount of the yeast 
colony was suspended in 100 µL of lysis buffer con-
taining 100 mM Tris–HCl, 0.5% SDS, and 30 mM EDTA 
and boiled for 15 min at 100ºC. A solution of potas-
Figure 1. Lesions and oral candidiasis (black hairy tongue) 
in patients with pemphigus.
Figure 2. Results of PCR electrophoresis: line M: 100 bp Mo-
lecular Marker; line 1: standard positive control; lines 2-9: 
Candida spp.
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sium acetate (2.5 M) was then added to the lysate, 
held on ice for 1 h, centrifuged at 12,000 rpm for 5 
min, and transferred to a new tube. The yeast DNA in 
the supernatant was washed twice with ethanol and 
air dried and re-suspended in 50 µL of distilled water 
prior to use for PCR. The purity and quantity of DNA 
were evaluated with absorbance ratio of A260/A280 
and nano-drop reading results.
Amplification and sequencing of the ITS 
regions
A set of universal primers (ITS1, 5’-TCCGTAGGT-
GAACCTGCG-3’, and ITS4, 5’-TCCTCCGCTTATTGATAT-
GC-3’) (Meta-bion International, Martinsried, Germa-
ny) were employed for amplification of the internal 
transcribed spacer (ITS) region of the ITS1-5.8S-ITS2 
segment of the ribosomal DNA gene. PCR amplifica-
tion was carried out in a final volume of 50 μL consist-
ing of 5 μL of ×10 PCR buffer, 1.5 mM MgCl2, 0.8 mM 
deoxynucleoside triphosphates (0.2 mM each), 1.2 U 
of Taq DNA polymerase (Roche Molecular Biochemi-
cals, Mannheim, Germany), 0.5 μM of each primer, 2 
µL of DNA template, and eventually with distilled wa-
ter to a final volume. An initial denaturation step at 
95ºC for 5 min was followed by 30 cycles of denatur-
ation at 94ºC for 30 sec, annealing at 64ºC for 50 sec, 
and extended at 72ºC for 1 min, with a final extension 
step at 72ºC for 7 min, and kept at 4ºC for 5 min. Nega-
tive controls were also used in each set of reactions. 
The PCR product was electrophoresed on 1.2% aga-
rose gel and stained with ethidium bromide. The PCR 
products were then purified and sequenced (Bioneer 
Company, South Korea). The sequence results were 
processed using the web-based blasting program 
and basic local alignment search tool (http://www.
ncbi.nlm.nih.gov/BLAST). Finally, the obtained data 
were compared with those in the NCBI/Genebank 
database.
Antifungal susceptibility test
Antifungal activity of six antifungal drugs includ-
ing fluconazole, itraconazole, ketoconazole, posacon-
azole, econazole, and amphotericin B were evaluated 
against the isolates according to the CLSI M-44 A pro-
tocol. Standard strains of C. albicans (ATCC10261) and 
C. tropicalis (ATCC750) were used as controls.
Statistical analysis:
The Fisher’s exact test was used for data statistical 
analysis and a P value of ≤0.05 was considered sig-
nificant.
RESULTS
Twenty percent of the patients presented with 
oral candidiasis (Figure 1). Candida albicans & dubli-
niensis, C. tropicalis, C. krusei, C. parapsilosis, and C. 
glabrata presented green, blue, white-pink, white, 
and purple colony colors on chromogenic media, 
respectively. The ITS region of extracted DNA was 
completely amplified in all yeast isolates (Figure 2). 
The sequence results of PCR products demonstrate 3 
species of Candida in the patient group and 4 species 
of Candida in the control group.
In the patient group, Candida albicans was the 
most common agent 22 (88%), followed by C. glabra-
ta (2; 8%) and C. dubliniensis (1; 4%). 
The results of antifungal activity against the iso-
lates are presented in Table 1. In the patient group, 
all of the isolates were sensitive to econazole and am-
photericin B.
One patient affected with C. glabrata showed 
a profile resistant to fluconazole, itraconazole, and 
posaconazole and an intermediate profile to itracon-
azole, simultaneously.
In the control group, Candida albicans 16 (64%) 
was the most common agent. There was no signifi-
cant difference between two groups regarding C. al-
bicans as most common causative agent. The other 
species were C. krusei (5; 20%), C. tropicalis (2; 8%) and 
C. glabrata (2; 8%).
Ninety six percent of isolates were sensitive to six 
antifungal drugs. One isolate (C. glabrata) was resistant 
to fluconazole and showed an intermediate profile to 
itraconazole and ketoconazole. This isolate had no his-
tory of previous encounters with antifungal drugs. 
There was no significant relation between etio-
logical agents and resistance to antifungal drugs in 
the 2 groups.
DISCUSSION
Pemphigus vulgaris is an autoimmune bullous 
disease characterized by blister formation on the skin 
Table 1. Results of disk diffusion test on Candida spp isolates in patient and control groups
Itra Flu Eco Ket Pso Ampho Disc
S I R S I R S I R S I R S I R S I R
23 1 1 24 - 1 25 - - 23 2 - 24 - 1 25 - - Patients (25)
23 2 - 24 - 1 25 - - 24 1 - 25 - - 25 - - Controls (25)
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and oral mucosa. It affects mainly adults with an ap-
proximate incidence of 0.5-3.2 per 1,000,000 people 
annually (3). The best treatment for patients with PV 
is corticosteroid therapy, which often leads to several 
complications associated with a high dose of immu-
nosuppressive drugs (1). This condition may represent 
a risk factor for cutaneous and oral disorders, lead to 
periodontitis and microbial infections (6,9), and may 
sometimes mimics dermatophytosis (10). Kiran et al. 
(11) reported a wide range of bacteria colonized on 
the skin of patients with PV. Al-Dwibe et al. (12) re-
ported superficial fungal infections affecting the nails 
and skin among patients with bullous diseases. They 
isolated many genera of fungi including Candida, 
Trichophyton, Fusarium, and Rodotorola from patients. 
Candidiasis is the most common opportunist fungal 
diseases and Candida species comprise 25-50% of 
the oral cavity microbiota of healthy individuals (13). 
Candida albicans is the most common, followed by 
Candida glabrata as the second most frequent cause 
of candidiasis, accounting for approximately 15-25% 
of clinical cases (14).
C. glabrata is an opportunistic fungal pathogen 
the forms part of the normal microbial flora in hu-
mans and in immunocompromised patients, and as 
such presents a significant problem. C. glabrata is 
commonly found in the human gastrointestinal tract 
and can disseminate to cause invasive candidiasis 
and serious infections (15).
Oral candidiasis is the most common human fun-
gal infection and C. albicans is the most prevalent 
agent as a normal commensal of the mouth and gen-
erally causes no problems in healthy people (16). To 
our knowledge, there have been no studies on oral 
cavity mycoflora in patients with PV. We matched the 
patient (case) and control groups for age and sex. C. 
albicans was the most prevalent etiological agent in 
both groups. The variation of species in the control 
group was higher than the patient group. It seems 
that oral cavity conditions in patients with PV are the 
same as that of healthy people, and we were thus 
unable to observer higher relative prevalence of any 
specific Candida species. 
The pharmacological treatment of candidiasis 
can be divided into two procedures: topical thera-
py that is applied to the affected area and systemic 
drugs that are used when the infection is more wide-
spread (17). Azole and allylamine antifungal agents 
have added greatly to the therapeutic options for the 
treatment of fungal infections. Disk diffusion method 
is a commonly used method for antifungal suscep-
tibility testing (17). Pfaller et al. performed a global 
study on Candida species in 41 countries and found 
that increased number of isolation in C. glabrata (18). 
In that study, analyses of in vitro susceptibility of 31 
Candida species to fluconazole were evaluated by 
disk diffusion method and an increase in fluconazole 
resistance was seen in C. glabrata and C. albicans. In 
the present study, 96% of species in the control group 
were susceptible to six antifungal drugs, similarly to 
the patient group. C. glabrata have an inherently el-
evated tolerance to azole antifungals, and clinical iso-
lates generally exhibit a high inherent tolerance level 
to azole drugs (14).
In one patient with thrush infection, C. glabrata 
was identified as a causative agent and showed mul-
tidrug resistance to three antifungals. Similarly, C. gla-
brata was isolated in the control group and showed 
resistance to fluconazole and intermediate profile to 
the other azoles. This case had no history of previous 
encounters with azoles. It appears that inherently 
reduced azole susceptibilities in most clinical C. gla-
brata isolates could be involved.
CONCLUSION
In this study, various species of Candida were col-
lected from patients with oral lesions, and C. albicans 
was identified as the most common isolate. Because 
most of the isolates were sensitive to antifungals, 
multiple drug choices are available for treatment in 
patients with pemphigus vulgaris in case of oral in-
fection or probable systemic candidiasis.   
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